Related Experiment Video

Updated: Aug 1, 2025

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

8.3K

Super Carbonate Apatite-miR-497a-5p Complex Is a Promising Therapeutic Option against Inflammatory Bowel Disease

Naoto Tsujimura1, Takayuki Ogino1, Masayuki Hiraki2

  • 1Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Yamadaoka 2-2, Suita City 565-0871, Japan.

Pharmaceuticals (Basel, Switzerland)
|April 28, 2023
PubMed

Insights

A novel microRNA, miR-497a-5p, shows potential for treating inflammatory bowel disease (IBD). This microRNA activates a key signaling pathway and reduces inflammation in preclinical models, offering a new therapeutic avenue for IBD.

Area of Science:

  • Gastroenterology
  • Molecular Biology
  • Nanomedicine

Background:

  • Inflammatory bowel disease (IBD) incidence is rising globally.
  • Crohn's disease is linked to an inactivated TGF-β/Smad pathway due to Smad 7 overexpression.
  • MicroRNAs (miRNAs) offer potential for multi-target therapeutic strategies.

Purpose of the Study:

  • Identify miRNAs that activate the TGF-β/Smad pathway.
  • Evaluate the in vivo therapeutic efficacy of identified miRNAs for IBD.

Main Methods:

  • Smad binding element (SBE) reporter assays were used to identify candidate miRNAs.
  • miR-497a-5p's effect on TGF-β/Smad pathway components and inflammatory cytokines was assessed in cell lines.
  • Therapeutic efficacy was tested in a dextran sodium sulfate (DSS)-induced colitis mouse model using sCA nanoparticles for delivery.

Main Results:

  • miR-497a-5p enhanced TGF-β/Smad pathway activity, decreasing Smad 7 and increasing pSmad3 in various cell types.
  • miR-497a-5p suppressed inflammatory cytokine production (TNF-α, IL-12p40, IL-6) in LPS-stimulated macrophages.
  • Systemic delivery of sCA-miR-497a-5p restored colonic mucosa and reduced inflammation in a mouse colitis model.

Conclusions:

  • miR-497a-5p effectively activates the TGF-β/Smad pathway and reduces inflammation.
  • sCA nanoparticle-delivered miR-497a-5p demonstrates therapeutic potential for IBD.
  • Further research is warranted to explore sCA-miR-497a-5p as an IBD treatment.
Keywords:
TGF-βinflammatory bowel diseasemacrophagemiR-497a-5p

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.4K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.1K

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
186
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
161
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
210
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
245
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
370
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
164